Last reviewed · How we verify

Tillotts Pharma AG — Portfolio Competitive Intelligence Brief

Tillotts Pharma AG pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 5 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Mesalamin Mesalamin marketed Other
TP05 TP05 phase 3 Phosphodiesterase 4 (PDE4) inhibitor PDE4 Dermatology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AbbVie (prior sponsor, Abbott) · 1 shared drug class
  2. Alfasigma S.p.A. · 1 shared drug class
  3. Almirall, S.A. · 1 shared drug class
  4. Arcutis Biotherapeutics, Inc. · 1 shared drug class
  5. Galderma R&D · 1 shared drug class
  6. GlaxoSmithKline · 1 shared drug class
  7. LEO Pharma · 1 shared drug class
  8. Mallinckrodt · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Tillotts Pharma AG:

Cite this brief

Drug Landscape (2026). Tillotts Pharma AG — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/tillotts-pharma-ag. Accessed 2026-06-10.

Related